Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma (NASDAQ: LTRN), has achieved a significant milestone with the FDA's clearance of an Investigational New Drug (IND) application for STAR-001 (LP-184) in combination with spironolactone. This approval paves the way for a Phase Ib/2a clinical trial targeting glioblastoma multiforme (GBM) at first progression, a critical development for patients facing this highly aggressive brain cancer with limited treatment options.
The clinical trial aims to assess the safety, tolerability, and preliminary efficacy of STAR-001, a brain-penetrant DNA-damaging agent, when used alongside spironolactone. The combination therapy is designed to exploit DNA repair deficiencies through synthetic lethality, with spironolactone enhancing the effect by inducing NER deficiency in tumor cells. This innovative approach has garnered Orphan Drug and Fast Track designations from the FDA, underscoring its potential to address unmet medical needs in GBM treatment.
Building on data from an ongoing Phase 1a trial, the program leverages Lantern Pharma's AI-driven RADR(R) platform to identify optimal patient populations and accelerate development timelines. This strategic use of artificial intelligence in oncology drug development highlights Lantern Pharma's commitment to transforming the cost, time, and failure rate associated with bringing new therapies to market.
For more details on this groundbreaking development, visit https://ibn.fm/8ndAq. The progress of Lantern Pharma and its subsidiaries in the oncology space continues to be closely watched by investors and the medical community alike, as they harness the power of AI to advance cancer treatment.
